Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
- PMID: 21975269
- PMCID: PMC3266951
- DOI: 10.1016/S1473-3099(11)70247-X
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
Erratum in
- Lancet Infect Dis. 2012 Feb;12(2):98
Abstract
Background: Hormonal contraceptives are used widely but their effects on HIV-1 risk are unclear. We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners.
Methods: In this prospective study, we followed up 3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries. Among injectable and oral hormonal contraceptive users and non-users, we compared rates of HIV-1 acquisition by women and HIV-1 transmission from women to men. The primary outcome measure was HIV-1 seroconversion. We used Cox proportional hazards regression and marginal structural modelling to assess the effect of contraceptive use on HIV-1 risk.
Findings: Among 1314 couples in which the HIV-1-seronegative partner was female (median follow-up 18·0 [IQR 12·6-24·2] months), rates of HIV-1 acquisition were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not (adjusted hazard ratio 1·98, 95% CI 1·06-3·68, p=0·03). Among 2476 couples in which the HIV-1-seronegative partner was male (median follow-up 18·7 [IQR 12·8-24·2] months), rates of HIV-1 transmission from women to men were 2·61 per 100 person-years in couples in which women used hormonal contraception and 1·51 per 100 person-years in couples in which women did not use hormonal contraception (adjusted hazard ratio 1·97, 95% CI 1·12-3·45, p=0·02). Marginal structural model analyses generated much the same results to the Cox proportional hazards regression.
Interpretation: Women should be counselled about potentially increased risk of HIV-1 acquisition and transmission with hormonal contraception, especially injectable methods, and about the importance of dual protection with condoms to decrease HIV-1 risk. Non-hormonal or low-dose hormonal contraceptive methods should be considered for women with or at-risk for HIV-1.
Funding: US National Institutes of Health and the Bill & Melinda Gates Foundation.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Comment in
-
Hormonal contraception and HIV: an unanswered question.Lancet Infect Dis. 2012 Jan;12(1):2-3. doi: 10.1016/S1473-3099(11)70254-7. Epub 2011 Oct 3. Lancet Infect Dis. 2012. PMID: 21975268 No abstract available.
-
Challenges in assessing associations between hormonal contraceptive use and the risks of HIV-1 acquisition and transmission.Future Microbiol. 2012 Mar;7(3):315-8. doi: 10.2217/fmb.12.8. Future Microbiol. 2012. PMID: 22393886
-
Use of hormonal contraceptives and risk of HIV-1 transmission.Lancet Infect Dis. 2012 Jul;12(7):507-8; author reply 510-1. doi: 10.1016/S1473-3099(12)70112-3. Lancet Infect Dis. 2012. PMID: 22742626 No abstract available.
-
Use of hormonal contraceptives and risk of HIV-1 transmission.Lancet Infect Dis. 2012 Jul;12(7):507; author reply 510-1. doi: 10.1016/S1473-3099(12)70111-1. Lancet Infect Dis. 2012. PMID: 22742627 No abstract available.
-
Use of hormonal contraceptives and risk of HIV-1 transmission.Lancet Infect Dis. 2012 Jul;12(7):508; author reply 510-1. doi: 10.1016/S1473-3099(12)70114-7. Lancet Infect Dis. 2012. PMID: 22742628 No abstract available.
-
Use of hormonal contraceptives and risk of HIV-1 transmission.Lancet Infect Dis. 2012 Jul;12(7):508-9; author reply 510-1. doi: 10.1016/S1473-3099(12)70113-5. Lancet Infect Dis. 2012. PMID: 22742629 No abstract available.
-
Use of hormonal contraceptives and risk of HIV-1 transmission.Lancet Infect Dis. 2012 Jul;12(7):509-10; author reply 510-1. doi: 10.1016/S1473-3099(12)70110-X. Lancet Infect Dis. 2012. PMID: 22742630 No abstract available.
-
Use of hormonal contraceptives and risk of HIV-1 transmission.Lancet Infect Dis. 2012 Jul;12(7):509; author reply 510-1. doi: 10.1016/S1473-3099(12)70109-3. Lancet Infect Dis. 2012. PMID: 22742631 No abstract available.
-
Use of hormonal contraceptives and risk of HIV-1 transmission.Lancet Infect Dis. 2012 Jul;12(7):510; author reply 510-1. doi: 10.1016/S1473-3099(12)70115-9. Lancet Infect Dis. 2012. PMID: 22742633 No abstract available.
Similar articles
-
Hormonal contraceptive use and risk of HIV-1 disease progression.AIDS. 2013 Jan 14;27(2):261-7. doi: 10.1097/QAD.0b013e32835ad473. AIDS. 2013. PMID: 23079806 Free PMC article.
-
Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial.Contraception. 2016 Jan;93(1):25-31. doi: 10.1016/j.contraception.2015.10.010. Epub 2015 Oct 28. Contraception. 2016. PMID: 26519646 Free PMC article. Clinical Trial.
-
Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.Lancet Glob Health. 2015 Aug;3(8):e478-e486. doi: 10.1016/S2214-109X(15)00086-8. Epub 2015 Jun 17. Lancet Glob Health. 2015. PMID: 26094162 Free PMC article.
-
Hormonal contraception and HIV-1 transmission.Am J Reprod Immunol. 2011 Mar;65(3):302-7. doi: 10.1111/j.1600-0897.2010.00930.x. Epub 2010 Nov 19. Am J Reprod Immunol. 2011. PMID: 21087338 Free PMC article. Review.
-
Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence.AIDS. 2013 Feb 20;27(4):493-505. doi: 10.1097/QAD.0b013e32835ad539. AIDS. 2013. PMID: 23079808 Review.
Cited by
-
Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.PLoS One. 2024 Jul 15;19(7):e0306237. doi: 10.1371/journal.pone.0306237. eCollection 2024. PLoS One. 2024. PMID: 39008499 Free PMC article.
-
Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion.Clin Cancer Res. 2024 Nov 15;30(22):5073-5082. doi: 10.1158/1078-0432.CCR-24-0362. Clin Cancer Res. 2024. PMID: 38922360 Clinical Trial.
-
Establishing adherence-concentration-efficacy thresholds of TDF-FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF-FTC Benchmark Study.Front Reprod Health. 2024 May 27;6:1325257. doi: 10.3389/frph.2024.1325257. eCollection 2024. Front Reprod Health. 2024. PMID: 38860025 Free PMC article.
-
Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.PLoS One. 2024 May 9;19(5):e0299802. doi: 10.1371/journal.pone.0299802. eCollection 2024. PLoS One. 2024. PMID: 38722832 Free PMC article. Clinical Trial.
-
Systems analysis reveals differential expression of endocervical genes in African women randomized to DMPA-IM, LNG implant or cu-IUD.Clin Immunol. 2023 Oct;255:109750. doi: 10.1016/j.clim.2023.109750. Epub 2023 Sep 3. Clin Immunol. 2023. PMID: 37660744 Free PMC article. Clinical Trial.
References
-
- World Health Organization. Strategic Approaches to the Prevention of HIV Infection in Infants; Report of a WHO meeting; Morges Switzerland. 20–22 March 2002; 2003. [Accessed 15 December 2010.]. Available at: http://www.who.int/hiv/pub/mtct/en/StrategicApproachesE.pdf.
-
- Reynolds HW, Janowitz B, Wilcher R, Cates W. Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries. Sexually Transmitted Infections. 2008;84(Suppl 2):ii49–53. - PubMed
-
- Population Division, United Nations Department of Economic Social Affairs. [Accessed 25 January 2011.];World Contraceptive Use 2009. 2009 Available at: http://www.un.org/esa/population/publications/contraceptive2009/contrace....
-
- Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. The Journal of Infectious Diseases. 1991;163(2):233–239. - PubMed
-
- Kiddugavu M, Makumbi F, Wawer MJ, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS. 2003;17(2):233–240. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R03 HD068143-01A1/HD/NICHD NIH HHS/United States
- T32 AI007140-31/AI/NIAID NIH HHS/United States
- T32 AI007140/AI/NIAID NIH HHS/United States
- R01 AI083034-03/AI/NIAID NIH HHS/United States
- T32 AI007140-34/AI/NIAID NIH HHS/United States
- U01 AI038858/AI/NIAID NIH HHS/United States
- R01 AI083034/AI/NIAID NIH HHS/United States
- P30 AI027757-12/AI/NIAID NIH HHS/United States
- R01 AI083034-01/AI/NIAID NIH HHS/United States
- R03 HD068143/HD/NICHD NIH HHS/United States
- P30 AI027757/AI/NIAID NIH HHS/United States
- P30 AI027757-24/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
